Merck & Co., Inc. (known as MSD outside the United States and Canada) and Eisai Co., Ltd. have announced encouraging results from the first interim analysis of the Phase 3 LEAP-012 trial evaluating the efficacy of KEYTRUDA (pembrolizumab), an anti-PD-1 therapy by Merck, combined with LENVIMA (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor […]
NiKang Therapeutics Inc., a clinical-stage biotech company specializing in small molecule oncology medicines, has announced a significant clinical trial collaboration and supply agreement with F. Hoffmann-La Roche Ltd. (Roche). This partnership focuses on evaluating NiKang’s NKT2152, a novel small molecule that inhibits hypoxia-inducible factor 2α (HIF2α), in combination with Roche’s atezolizumab (Tecentriq) and bevacizumab (Avastin) […]
Terumo India, the Indian subsidiary of the globally recognized Terumo Corporation, has recently announced the launch of two innovative products, Occlusafe and LifePearl, aimed at enhancing the management of liver cancer. This introduction marks a significant advancement in the Indian healthcare sector, especially for the treatment of hepatocellular carcinoma (HCC), the most prevalent type of […]
the International Agency for Research on Cancer (IARC) and the Joint Expert Committee on Food Additives (JECFA), of the World Health Organization (WHO) and the Food and Agriculture Organization (FAO), issued assessments regarding the health impacts of the non-sugar sweetener aspartame. These agencies cited limited evidence linking aspartame to carcinogenicity in humans, leading to IARC […]
AstraZeneca’s IMFINZI (durvalumab) combined with IMJUDO (tremelimumab-actl) has demonstrated an enduring overall survival (OS) benefit in patients with advanced hepatocellular carcinoma (HCC), according to the updated results from the HIMALAYA Phase 3 trial. An unparalleled one in four patients were still alive four years after treatment with this novel combination therapy, marking the longest survival […]
Swedish biotech company Medivir has secured orphan medicinal product designation from the European Commission for MIV-818 for the treatment of hepatocellular carcinoma (HCC). The orphan medicinal product designation to the pro-drug in the European Union (EU) was granted in accordance with the opinion from the European Medicines Agency (EMA). Although hepatocellular carcinoma is considered to […]
Bristol Myers Squibb has secured approval for the combination of Opdivo (nivolumab) 1 mg/kg and Yervoy (ipilimumab) 3 mg/kg from the US Food and Drug Administration (FDA) for the treatment of hepatocellular carcinoma (HCC) in patients who were previously treated with sorafenib. Approval for the indication has been issued under accelerated approval on the basis […]
In a significant development for cancer treatment, Eisai and Merck have announced that the U.S. Food and Drug Administration (FDA) has approved Lenvima (lenvatinib) for the first-line treatment of hepatocellular carcinoma (HCC), the most common type of primary liver cancer in adults. This approval marks a pivotal advance, offering a new treatment option for patients […]